A closer look at “FDA Approves First Functional Cure Drug for Chronic Hepatitis B”, exactly as the source publishes it. Food and Drug Administration has approved the first drug that offers a functional cure for chronic hepatitis B, a liver infection affecting over 250 million people worldwide. The drug, developed by Gilead Sciences, targets the virus's ability to persist in liver cell The drug, developed by Gilead Sciences, targets the virus's ability to persist in liver cells, potentially freeing patients from lifelong daily medication.
Clinical trials showed that after 48 weeks of treatment, nearly 30% of participants achieved a functional cure, meaning the virus was undetectable in their blood six months after stopping therapy. This is a significant improvement over current treatments, which only suppress the virus but rarely eliminate it. The approval marks a turning point for patients at risk of cirrhosis and liver cancer, and it could reduce the global burden of hepatitis B, which claims nearly 900,000 lives each year. For the complete material, the listing points back to the source inside the network.